G. A. KOPPEL

2.3k total citations
38 papers, 1.7k citations indexed

About

G. A. KOPPEL is a scholar working on Organic Chemistry, Molecular Biology and Pharmacology. According to data from OpenAlex, G. A. KOPPEL has authored 38 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Organic Chemistry, 12 papers in Molecular Biology and 6 papers in Pharmacology. Recurrent topics in G. A. KOPPEL's work include Synthesis and Catalytic Reactions (6 papers), Neuroendocrine regulation and behavior (6 papers) and Synthesis of β-Lactam Compounds (5 papers). G. A. KOPPEL is often cited by papers focused on Synthesis and Catalytic Reactions (6 papers), Neuroendocrine regulation and behavior (6 papers) and Synthesis of β-Lactam Compounds (5 papers). G. A. KOPPEL collaborates with scholars based in United States, Denmark and Germany. G. A. KOPPEL's co-authors include Craig F. Ferris, Kenneth W. Perry, Ray W. Fuller, Richard H. Melloni, Yvon Delville, Eileen M. Briley, Christian C. Felder, Steve Briggs, Marleen Kawahara and Craig Gérard and has published in prestigious journals such as Journal of the American Chemical Society, The Journal of Experimental Medicine and Journal of Neuroscience.

In The Last Decade

G. A. KOPPEL

37 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. A. KOPPEL United States 18 513 449 434 369 330 38 1.7k
N C Lan United States 19 129 0.3× 826 1.8× 194 0.4× 706 1.9× 152 0.5× 30 1.8k
Valér Csernus Hungary 29 198 0.4× 596 1.3× 243 0.6× 633 1.7× 77 0.2× 90 2.6k
Jean‐Claude Beauvillain France 30 141 0.3× 876 2.0× 346 0.8× 1.0k 2.8× 116 0.4× 72 2.9k
Yoshiaki Isobe Japan 26 81 0.2× 361 0.8× 214 0.5× 573 1.6× 462 1.4× 106 2.2k
Nancy C. Lan United States 28 112 0.2× 1.1k 2.4× 335 0.8× 972 2.6× 157 0.5× 41 2.9k
Douglas J. Pettibone United States 32 278 0.5× 1.9k 4.2× 405 0.9× 2.0k 5.3× 403 1.2× 98 4.5k
Deborra Mullins United States 21 106 0.2× 418 0.9× 142 0.3× 508 1.4× 110 0.3× 31 1.1k
Christine F. Höhmann United States 27 264 0.5× 883 2.0× 198 0.5× 791 2.1× 50 0.2× 55 1.9k
Richard Alonso France 19 419 0.8× 794 1.8× 167 0.4× 549 1.5× 24 0.1× 40 1.6k
Soledad Valera Switzerland 10 227 0.4× 683 1.5× 228 0.5× 1.6k 4.4× 73 0.2× 10 2.7k

Countries citing papers authored by G. A. KOPPEL

Since Specialization
Citations

This map shows the geographic impact of G. A. KOPPEL's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. A. KOPPEL with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. A. KOPPEL more than expected).

Fields of papers citing papers by G. A. KOPPEL

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. A. KOPPEL. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. A. KOPPEL. The network helps show where G. A. KOPPEL may publish in the future.

Co-authorship network of co-authors of G. A. KOPPEL

This figure shows the co-authorship network connecting the top 25 collaborators of G. A. KOPPEL. A scholar is included among the top collaborators of G. A. KOPPEL based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. A. KOPPEL. G. A. KOPPEL is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
King, Jean A., Lisa A. Zuccarelli, Craig F. Ferris, et al.. (2009). Clavulanic acid: A competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects. Pharmacology Biochemistry and Behavior. 93(2). 112–120. 38 indexed citations
2.
Simon, Neal G., Christophe Guillon, Ned D. Heindel, et al.. (2008). Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments. PubMed. 3(2). 77–93. 39 indexed citations
3.
Ferris, Craig F., Shi‐fang Lu, Tara Messenger, et al.. (2006). Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacology Biochemistry and Behavior. 83(2). 169–174. 80 indexed citations
4.
Guillon, Christophe, G. A. KOPPEL, Michael Brownstein, et al.. (2006). Azetidinones as vasopressin V1a antagonists. Bioorganic & Medicinal Chemistry. 15(5). 2054–2080. 58 indexed citations
5.
Ferris, Craig F., Mads Frederik Rasmussen, Tara Messenger, & G. A. KOPPEL. (2001). Vasopressin-dependent flank marking in golden hamsters is suppressed by drugs used in the treatment of obsessive-compulsive disorder. BMC Neuroscience. 2(1). 10–10. 13 indexed citations
6.
Siegel, Miles G., Michael O. Chaney, Robert F. Bruns, et al.. (1999). Rapid parallel synthesis applied to the optimization of a series of potent nonpeptide neuropeptide Y-1 receptor antagonists. Tetrahedron. 55(39). 11619–11639. 11 indexed citations
7.
Felder, Christian C., Eileen M. Briley, Miklós Palkovits, et al.. (1996). Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Letters. 393(2-3). 231–235. 276 indexed citations
8.
Bryant, Henry U., David L. Nelson, Donald Button, et al.. (1996). A novel class of 5-HT2a receptor antagonists: Aryl aminoguanidines. Life Sciences. 59(15). 1259–1268. 22 indexed citations
9.
Apelgren, L D, et al.. (1993). Chemoimmunoconjugate development for ovarian carcinoma therapy: Preclinical studies with vinca alkaloid-monoclonal antibody constructs. Bioconjugate Chemistry. 4(2). 121–126. 8 indexed citations
10.
KOPPEL, G. A.. (1990). Recent advances with monoclonal antibody drug targeting for the treatment of human cancer. Bioconjugate Chemistry. 1(1). 13–23. 50 indexed citations
11.
12.
KOPPEL, G. A., et al.. (1978). ChemInform Abstract: DIRECT TWO‐STEP CONVERSION OF PENICILLINS TO 3‐ACETOXYMETHYLCEPHEMS. Chemischer Informationsdienst. 9(17). 1 indexed citations
13.
KOPPEL, G. A., et al.. (1978). Total synthesis of nocardicin A. Synthesis of 3-ANA and nocardicin A. Journal of the American Chemical Society. 100(12). 3933–3935. 30 indexed citations
14.
KOPPEL, G. A., et al.. (1978). Direct two-step conversion of penicillins to 3-acetoxymethylcephems. Journal of the American Chemical Society. 100(1). 288–289. 11 indexed citations
15.
KOPPEL, G. A., et al.. (1976). Substrate Inhibition of Beta-Lactamases, a Method for Predicting Enzymatic Stability of Cephalosporins. Antimicrobial Agents and Chemotherapy. 10(3). 470–475. 18 indexed citations
16.
KOPPEL, G. A. & S. KUKOLJA. (1975). The oxoazetidinesulphenic acid anion: S-vs. O-alkylation. Journal of the Chemical Society Chemical Communications. 57–57. 9 indexed citations
17.
KOPPEL, G. A. & M. D. KINNICK. (1974). Carboxyvinylation; a one-step synthesis of α,β-unsaturated acids. Tetrahedron Letters. 15(9). 711–713. 9 indexed citations
18.
Ho, Peter P.K., et al.. (1973). BIOCHEMICAL AND MICROBIOLOGICAL STUDIES ON 7-METHOXYCEPHALOSPORINS. The Journal of Antibiotics. 26(5). 313–314. 17 indexed citations
19.
KOPPEL, G. A.. (1973). Direct C6 epimerization of penicillin V methyl ester via the vicinal dianion. Tetrahedron Letters. 14(43). 4233–4236. 6 indexed citations
20.
Danishefsky, Samuel J., James F. Eggler, & G. A. KOPPEL. (1969). Reaction of methyl β-vinylacrylate with formylcycloalkanones.. Tetrahedron Letters. 10(50). 4333–4334. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N C Lan Breakdown of academic impact, for papers by Valér Csernus Breakdown of academic impact, for papers by Jean‐Claude Beauvillain Breakdown of academic impact, for papers by Yoshiaki Isobe Breakdown of academic impact, for papers by Nancy C. Lan Breakdown of academic impact, for papers by Douglas J. Pettibone Breakdown of academic impact, for papers by Deborra Mullins Breakdown of academic impact, for papers by Christine F. Höhmann Breakdown of academic impact, for papers by Richard Alonso Breakdown of academic impact, for papers by Soledad Valera
Rankless by CCL
2026